GSK’s (GSK) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their hold rating on shares of GSK (LON:GSK) in a research note issued to investors on Monday, Marketbeat reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,450 ($19.55) price target on the stock.

A number of other analysts also recently issued reports on GSK. Shore Capital reissued a “buy” rating and set a GBX 2,000 ($26.96) price objective on shares of GSK in a research report on Friday. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research report on Friday. Finally, Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,600 ($21.57) target price on shares of GSK in a research report on Friday.

GSK Stock Down 0.3%

GSK stock opened at GBX 1,344 ($18.12) on Monday. The firm has a 50 day moving average of GBX 1,435.32 and a 200 day moving average of GBX 1,423.08. The stock has a market capitalization of £54.54 billion, a PE ratio of 21.71, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 52 week low of GBX 1,242.50 ($16.75) and a 52 week high of GBX 1,678.68 ($22.63).

GSK (LON:GSK) last announced its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Sell-side analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In related news, insider Wendy Becker acquired 545 shares of the firm’s stock in a transaction dated Friday, June 20th. The stock was acquired at an average price of GBX 1,435 ($19.34) per share, for a total transaction of £7,820.75 ($10,542.94). Also, insider Jonathan Symonds bought 1,350 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average price of GBX 1,435 ($19.34) per share, with a total value of £19,372.50 ($26,115.53). In the last quarter, insiders purchased 1,905 shares of company stock worth $2,732,835. 1.61% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.